25 XP   0   0   10

Medicamen Biotech Limited
Buy, Hold or Sell?

Let's analyse Medicamen together

PenkeI guess you are interested in Medicamen Biotech Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medicamen Biotech Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Medicamen Biotech Limited

I send you an email if I find something interesting about Medicamen Biotech Limited.

Quick analysis of Medicamen (30 sec.)










What can you expect buying and holding a share of Medicamen? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR157.22
Expected worth in 1 year
INR168.30
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
INR11.08
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
INR579.60
Expected price per share
INR454.65 - INR688.97
How sure are you?
50%

1. Valuation of Medicamen (5 min.)




Live pricePrice per Share (EOD)

INR579.60

2. Growth of Medicamen (5 min.)




Is Medicamen growing?

Current yearPrevious yearGrowGrow %
How rich?$23.9m$19.9m$3.6m15.5%

How much money is Medicamen making?

Current yearPrevious yearGrowGrow %
Making money$343.5k$454.1k-$110.5k-32.2%
Net Profit Margin6.9%11.2%--

How much money comes from the company's main activities?

3. Financial Health of Medicamen (5 min.)




What can you expect buying and holding a share of Medicamen? (5 min.)

Welcome investor! Medicamen's management wants to use your money to grow the business. In return you get a share of Medicamen.

What can you expect buying and holding a share of Medicamen?

First you should know what it really means to hold a share of Medicamen. And how you can make/lose money.

Speculation

The Price per Share of Medicamen is INR579.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medicamen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medicamen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR157.22. Based on the TTM, the Book Value Change Per Share is INR2.77 per quarter. Based on the YOY, the Book Value Change Per Share is INR7.73 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medicamen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.020.0%0.030.0%0.030.0%0.030.0%0.030.0%
Usd Book Value Change Per Share0.000.0%0.030.0%0.090.0%0.160.0%0.160.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.030.0%0.090.0%0.160.0%0.160.0%
Usd Price Per Share7.24-8.01-9.50-6.72-6.72-
Price to Earnings Ratio94.45-86.66-73.53-59.62-59.62-
Price-to-Total Gains Ratio119.34-33.15-111.84-111.84-
Price to Book Ratio3.84-4.32-6.02-4.09-4.09-
Price-to-Total Gains Ratio119.34-33.15-111.84-111.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.9552
Number of shares143
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.16
Usd Total Gains Per Share0.030.16
Gains per Quarter (143 shares)4.7522.48
Gains per Year (143 shares)19.0289.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1019909080
2038280180170
3057470270260
4076660360350
5095850450440
601141040540530
701331230630620
801521420719710
901711610809800
1001901800899890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%12.00.00.0100.0%12.00.00.0100.0%12.00.00.0100.0%
Book Value Change Per Share2.00.02.050.0%6.00.06.050.0%6.00.06.050.0%6.00.06.050.0%6.00.06.050.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share2.00.02.050.0%6.00.06.050.0%6.00.06.050.0%6.00.06.050.0%6.00.06.050.0%

Fundamentals of Medicamen

About Medicamen Biotech Limited

Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. It also provides oral solid and liquid products. The company's products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system. Medicamen Biotech Limited was incorporated in 1993 and is based in New Delhi, India.

Fundamental data was last updated by Penke on 2024-04-14 04:17:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Medicamen Biotech Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Medicamen earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 4.4% means that ₹0.04 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medicamen Biotech Limited:

  • The MRQ is 4.4%. The company is making a profit. +1
  • The TTM is 6.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ4.4%TTM6.9%-2.5%
TTM6.9%YOY11.2%-4.3%
TTM6.9%5Y10.8%-3.9%
5Y10.8%10Y10.8%0.0%
1.1.2. Return on Assets

Shows how efficient Medicamen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Assets means that Medicamen generated ₹0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medicamen Biotech Limited:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.7%TTM1.0%-0.3%
TTM1.0%YOY1.6%-0.6%
TTM1.0%5Y1.5%-0.5%
5Y1.5%10Y1.5%0.0%
1.1.3. Return on Equity

Shows how efficient Medicamen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.0% Return on Equity means Medicamen generated ₹0.01 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medicamen Biotech Limited:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.5%-0.5%
TTM1.5%YOY2.3%-0.9%
TTM1.5%5Y2.2%-0.7%
5Y2.2%10Y2.2%0.0%

1.2. Operating Efficiency of Medicamen Biotech Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Medicamen is operating .

  • Measures how much profit Medicamen makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 8.4% means the company generated ₹0.08  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medicamen Biotech Limited:

  • The MRQ is 8.4%. The company is operating less efficient.
  • The TTM is 10.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ8.4%TTM10.8%-2.3%
TTM10.8%YOY14.7%-3.9%
TTM10.8%5Y14.5%-3.7%
5Y14.5%10Y14.5%0.0%
1.2.2. Operating Ratio

Measures how efficient Medicamen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.93 means that the operating costs are ₹0.93 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Medicamen Biotech Limited:

  • The MRQ is 0.934. The company is less efficient in keeping operating costs low.
  • The TTM is 0.904. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.934TTM0.904+0.029
TTM0.904YOY0.876+0.028
TTM0.9045Y0.870+0.035
5Y0.87010Y0.8700.000

1.3. Liquidity of Medicamen Biotech Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Medicamen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.00 means the company has ₹0.00 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Medicamen Biotech Limited:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.961-0.961
TTM0.961YOY0.970-0.009
TTM0.9615Y1.237-0.276
5Y1.23710Y1.2370.000
1.3.2. Quick Ratio

Measures if Medicamen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₹0.00 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medicamen Biotech Limited:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.581-0.581
TTM0.581YOY0.613-0.031
TTM0.5815Y0.781-0.199
5Y0.78110Y0.7810.000

1.4. Solvency of Medicamen Biotech Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Medicamen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medicamen to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.33 means that Medicamen assets are financed with 32.8% credit (debt) and the remaining percentage (100% - 32.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medicamen Biotech Limited:

  • The MRQ is 0.328. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.317. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.317+0.011
TTM0.317YOY0.316+0.000
TTM0.3175Y0.318-0.002
5Y0.31810Y0.3180.000
1.4.2. Debt to Equity Ratio

Measures if Medicamen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 48.8% means that company has ₹0.49 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medicamen Biotech Limited:

  • The MRQ is 0.488. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.464. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.488TTM0.464+0.024
TTM0.464YOY0.466-0.003
TTM0.4645Y0.469-0.005
5Y0.46910Y0.4690.000

2. Market Valuation of Medicamen Biotech Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Medicamen generates.

  • Above 15 is considered overpriced but always compare Medicamen to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 94.45 means the investor is paying ₹94.45 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medicamen Biotech Limited:

  • The EOD is 90.760. Based on the earnings, the company is expensive. -2
  • The MRQ is 94.448. Based on the earnings, the company is expensive. -2
  • The TTM is 86.658. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD90.760MRQ94.448-3.688
MRQ94.448TTM86.658+7.790
TTM86.658YOY73.529+13.129
TTM86.6585Y59.618+27.040
5Y59.61810Y59.6180.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medicamen Biotech Limited:

  • The EOD is 51.037. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 53.111. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 61.369. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD51.037MRQ53.111-2.074
MRQ53.111TTM61.369-8.258
TTM61.369YOY-+61.369
TTM61.3695Y20.456+40.913
5Y20.45610Y20.4560.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Medicamen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 3.84 means the investor is paying ₹3.84 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Medicamen Biotech Limited:

  • The EOD is 3.687. Based on the equity, the company is fair priced.
  • The MRQ is 3.836. Based on the equity, the company is fair priced.
  • The TTM is 4.320. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.687MRQ3.836-0.150
MRQ3.836TTM4.320-0.484
TTM4.320YOY6.019-1.699
TTM4.3205Y4.088+0.232
5Y4.08810Y4.0880.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Medicamen Biotech Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.771-100%7.735-100%13.102-100%13.102-100%
Book Value Per Share--157.220154.670+2%130.668+20%131.779+19%131.779+19%
Current Ratio---0.961-100%0.970-100%1.237-100%1.237-100%
Debt To Asset Ratio--0.3280.317+4%0.316+4%0.318+3%0.318+3%
Debt To Equity Ratio--0.4880.464+5%0.466+5%0.469+4%0.469+4%
Dividend Per Share----0%-0%-0%-0%
Eps--1.5972.276-30%2.694-41%2.692-41%2.692-41%
Free Cash Flow Per Share--2.8392.730+4%--2.730+4%2.730+4%
Free Cash Flow To Equity Per Share--2.8392.730+4%--2.730+4%2.730+4%
Gross Profit Margin--1.0000.952+5%1.0000%0.984+2%0.984+2%
Market Cap7369382160.000-4%7668810990.0008485724040.000-10%10064718427.500-24%7123937402.500+8%7123937402.500+8%
Net Profit Margin--0.0440.069-36%0.112-61%0.108-59%0.108-59%
Operating Margin--0.0840.108-22%0.147-43%0.145-42%0.145-42%
Operating Ratio--0.9340.904+3%0.876+7%0.870+7%0.870+7%
Pb Ratio3.687-4%3.8364.320-11%6.019-36%4.088-6%4.088-6%
Pe Ratio90.760-4%94.44886.658+9%73.529+28%59.618+58%59.618+58%
Price Per Share579.600-4%603.150667.400-10%791.588-24%560.296+8%560.296+8%
Price To Free Cash Flow Ratio51.037-4%53.11161.369-13%-+100%20.456+160%20.456+160%
Quick Ratio---0.581-100%0.613-100%0.781-100%0.781-100%
Return On Assets--0.0070.010-32%0.016-57%0.015-54%0.015-54%
Return On Equity--0.0100.015-31%0.023-56%0.022-54%0.022-54%
Total Gains Per Share---2.771-100%7.735-100%13.102-100%13.102-100%
Usd Book Value--23987916.00023598804.000+2%19936638.006+20%20106233.484+19%20106233.484+19%
Usd Book Value Change Per Share---0.033-100%0.093-100%0.157-100%0.157-100%
Usd Book Value Per Share--1.8871.856+2%1.568+20%1.581+19%1.581+19%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0190.027-30%0.032-41%0.032-41%0.032-41%
Usd Free Cash Flow--433176.000416496.000+4%-+100%138832.000+212%138832.000+212%
Usd Free Cash Flow Per Share--0.0340.033+4%--0.033+4%0.033+4%
Usd Free Cash Flow To Equity Per Share--0.0340.033+4%--0.033+4%0.033+4%
Usd Market Cap88432585.920-4%92025731.880101828688.480-10%120776621.130-24%85487248.830+8%85487248.830+8%
Usd Price Per Share6.955-4%7.2388.009-10%9.499-24%6.724+8%6.724+8%
Usd Profit--243588.000343575.000-29%454110.000-46%423880.399-43%423880.399-43%
Usd Revenue--5580264.0005119563.000+9%4058700.000+37%4198722.827+33%4198722.827+33%
Usd Total Gains Per Share---0.033-100%0.093-100%0.157-100%0.157-100%
 EOD+4 -3MRQTTM+13 -20YOY+7 -215Y+14 -1910Y+14 -19

3.2. Fundamental Score

Let's check the fundamental score of Medicamen Biotech Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1590.760
Price to Book Ratio (EOD)Between0-13.687
Net Profit Margin (MRQ)Greater than00.044
Operating Margin (MRQ)Greater than00.084
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.000
Debt to Asset Ratio (MRQ)Less than10.328
Debt to Equity Ratio (MRQ)Less than10.488
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.007
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Medicamen Biotech Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5077.068
Ma 20Greater thanMa 50442.483
Ma 50Greater thanMa 100453.277
Ma 100Greater thanMa 200508.145
OpenGreater thanClose613.900
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in INR. All numbers in thousands.

Summary
 As reported
Total Liabilities 0
Total Stockholder Equity+ 0
Total Assets = 0

Assets

Total Current Assets
Total Current Assets  (as reported)0
Total Current Assets  (calculated)0
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities
Total Current Liabilities  (as reported)0
Total Current Liabilities  (calculated)0
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)0
+/-0
Other
Common Stock Shares Outstanding 12,651



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302009-03-312008-03-31
> Total Assets 
0
458,106
0
0
689,072
0
652,593
0
652,342
0
600,498
0
645,789
0
674,959
0
686,626
0
675,621
0
600,180
0
666,454
0
734,006
0
889,776
0
1,175,505
0
1,238,133
0
1,365,926
0
0
0
1,812,827
0
1,846,361
0
1,940,071
2,034,550
2,034,550
2,256,937
2,256,937
0
2,586,623
0
2,785,173
0
2,974,073
0
02,974,07302,785,17302,586,62302,256,9372,256,9372,034,5502,034,5501,940,07101,846,36101,812,8270001,365,92601,238,13301,175,5050889,7760734,0060666,4540600,1800675,6210686,6260674,9590645,7890600,4980652,3420652,5930689,07200458,1060
   > Total Current Assets 
0
274,928
0
0
453,015
0
417,127
0
419,093
0
374,601
0
419,478
0
463,293
0
485,085
0
479,417
0
405,954
0
475,968
0
533,803
0
678,801
0
909,857
0
954,761
0
961,685
0
0
0
1,041,311
0
968,821
0
960,328
1,014,507
1,014,507
1,230,380
1,230,380
0
1,529,326
305,502
1,633,627
207,788
1,754,967
0
01,754,967207,7881,633,627305,5021,529,32601,230,3801,230,3801,014,5071,014,507960,3280968,82101,041,311000961,6850954,7610909,8570678,8010533,8030475,9680405,9540479,4170485,0850463,2930419,4780374,6010419,0930417,1270453,01500274,9280
       Cash And Cash Equivalents 
0
8,905
0
0
29,063
0
24,542
0
1,605
0
20,508
0
9,834
0
25,266
0
6,609
0
26,623
0
27,160
0
35,948
0
29,689
0
2,282
0
216,377
0
123,015
0
73,502
0
0
0
17,096
0
31,644
0
16,568
37,562
37,562
38,248
38,248
0
305,502
0
207,788
-207,788
134,285
0
0134,285-207,788207,7880305,502038,24838,24837,56237,56216,568031,644017,09600073,5020123,0150216,37702,282029,689035,948027,160026,62306,609025,26609,834020,50801,605024,542029,063008,9050
       Short-term Investments 
0
0
0
0
200
0
200
0
200
0
200
0
200
0
200
0
200
0
200
0
200
0
700
0
700
0
54,129
0
700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
181,859
415,576
0
0
00415,576181,8590000000000000000000700054,129070007000200020002000200020002000200020002000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
574,830
0
619,207
634,019
634,019
684,873
684,873
0
713,172
0
721,840
0
786,941
0
0786,9410721,8400713,1720684,873684,873634,019634,019619,2070574,83000000000000000000000000000000000000000
       Other Current Assets 
0
192,271
0
0
297,507
0
255,199
0
266,044
0
246,512
0
281,072
0
341,222
0
343,640
0
310,029
0
267,218
0
327,554
0
365,515
0
437,561
0
550,438
0
699,643
0
735,580
0
0
0
854,641
0
283,662
0
272,515
225,567
225,567
237,162
237,162
0
222,168
0
253,426
0
271,072
0
0271,0720253,4260222,1680237,162237,162225,567225,567272,5150283,6620854,641000735,5800699,6430550,4380437,5610365,5150327,5540267,2180310,0290343,6400341,2220281,0720246,5120266,0440255,1990297,50700192,2710
   > Long-term Assets 
0
183,178
0
0
236,056
0
235,465
0
233,249
0
225,897
0
226,312
0
211,666
0
201,542
0
196,204
0
194,226
0
190,486
0
200,203
0
210,975
0
265,648
0
283,371
0
404,241
0
0
0
771,515
0
877,540
0
979,742
1,020,043
1,020,043
1,026,557
1,026,557
0
1,057,297
0
1,151,546
0
1,219,106
0
01,219,10601,151,54601,057,29701,026,5571,026,5571,020,0431,020,043979,7420877,5400771,515000404,2410283,3710265,6480210,9750200,2030190,4860194,2260196,2040201,5420211,6660226,3120225,8970233,2490235,4650236,05600183,1780
       Property Plant Equipment 
0
183,178
0
0
231,608
0
230,931
0
228,922
0
221,779
0
222,422
0
207,959
0
197,966
0
192,650
0
83,950
0
187,153
0
194,782
0
207,691
0
252,972
0
270,524
0
388,051
0
0
0
739,210
0
824,248
0
894,349
928,186
928,186
921,173
921,173
0
925,400
0
917,588
0
921,986
0
0921,9860917,5880925,4000921,173921,173928,186928,186894,3490824,2480739,210000388,0510270,5240252,9720207,6910194,7820187,153083,9500192,6500197,9660207,9590222,4220221,7790228,9220230,9310231,60800183,1780
       Intangible Assets 
0
0
0
0
0
0
0
0
1,178
0
0
0
762
0
0
0
397
0
0
0
307
0
0
0
0
0
218
0
3,169
0
0
0
3,343
0
0
0
2,691
0
0
0
2,042
0
0
3,598
3,598
0
4,387
0
8,977
0
8,042
0
08,04208,97704,38703,5983,598002,0420002,6910003,3430003,1690218000003070003970007620001,17800000000
       Other Assets 
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
83,351
0
87,815
0
101,785
0
127,510
0
224,981
0
0
0
000224,9810127,5100101,785087,815083,3510000000001000000000000000000000001000000
> Total Liabilities 
0
328,501
0
0
488,058
0
466,090
0
495,168
0
433,664
0
480,409
0
506,279
0
514,780
0
500,111
0
421,093
0
427,437
0
466,197
0
518,515
0
429,426
0
424,236
0
499,590
0
0
0
600,664
0
578,571
0
611,175
634,137
634,137
792,239
792,239
0
728,548
0
851,032
0
975,080
0
0975,0800851,0320728,5480792,239792,239634,137634,137611,1750578,5710600,664000499,5900424,2360429,4260518,5150466,1970427,4370421,0930500,1110514,7800506,2790480,4090433,6640495,1680466,0900488,05800328,5010
   > Total Current Liabilities 
0
236,474
0
0
471,149
0
444,696
0
477,308
0
415,623
0
456,066
0
482,725
0
447,428
0
436,877
0
372,429
0
385,516
0
426,666
0
482,647
0
412,080
0
408,125
0
485,436
0
0
0
564,836
0
487,982
0
532,740
559,178
559,178
726,908
726,908
0
699,791
0
825,735
0
940,685
0
0940,6850825,7350699,7910726,908726,908559,178559,178532,7400487,9820564,836000485,4360408,1250412,0800482,6470426,6660385,5160372,4290436,8770447,4280482,7250456,0660415,6230477,3080444,6960471,14900236,4740
       Short-term Debt 
0
0
0
0
127,368
0
164,483
0
167,351
0
164,874
0
152,522
0
158,627
0
161,254
0
151,583
0
159,393
0
111,309
0
182,873
0
144,154
0
143,549
0
30,635
0
117,341
0
0
0
91,130
0
112,119
0
124,147
194,713
194,713
207,223
207,223
0
275,457
0
233,131
0
270,931
0
0270,9310233,1310275,4570207,223207,223194,713194,713124,1470112,119091,130000117,341030,6350143,5490144,1540182,8730111,3090159,3930151,5830161,2540158,6270152,5220164,8740167,3510164,4830127,3680000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
124,147
0
194,713
0
192,749
0
275,457
0
233,131
0
270,931
0
0270,9310233,1310275,4570192,7490194,7130124,1470000000000000000000000000000000000000000
       Accounts payable 
0
141,392
0
0
317,482
0
262,151
0
212,040
0
224,271
0
244,388
0
299,327
0
235,942
0
254,210
0
171,626
0
216,406
0
225,362
0
254,633
0
201,470
0
319,135
0
305,698
0
0
0
313,292
0
285,070
0
305,231
306,484
306,484
433,000
433,000
0
389,485
0
475,859
0
559,269
0
0559,2690475,8590389,4850433,000433,000306,484306,484305,2310285,0700313,292000305,6980319,1350201,4700254,6330225,3620216,4060171,6260254,2100235,9420299,3270244,3880224,2710212,0400262,1510317,48200141,3920
       Other Current Liabilities 
0
95,082
0
0
26,299
0
18,062
0
97,917
0
26,478
0
59,156
0
24,771
0
50,232
0
31,084
0
41,410
0
57,801
0
18,431
0
66,519
0
67,061
0
58,355
0
62,396
0
0
0
160,414
0
63,651
0
400
34,532
34,532
86,686
20,349
0
14,201
0
72,846
0
79,551
0
079,551072,846014,201020,34986,68634,53234,532400063,6510160,41400062,396058,355067,061066,519018,431057,801041,410031,084050,232024,771059,156026,478097,917018,062026,2990095,0820
   > Long-term Liabilities 
0
92,026
0
0
16,910
0
21,394
0
17,860
0
18,041
0
24,342
0
23,554
0
67,352
0
63,234
0
48,664
0
41,921
0
39,531
0
35,868
0
17,346
0
16,111
0
14,154
0
0
0
35,828
0
90,589
0
78,436
74,959
74,959
65,330
65,330
0
28,757
0
25,297
0
34,395
0
034,395025,297028,757065,33065,33074,95974,95978,436090,589035,82800014,154016,111017,346035,868039,531041,921048,664063,234067,352023,554024,342018,041017,860021,394016,9100092,0260
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,390
0
18,426
0
14,594
0
19,325
0
16,601
0
0
0
00016,601019,325014,594018,426014,3900000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,597
0
77,479
0
88,169
0
106,102
0
0
0
0
0
00000106,102088,169077,479075,5970000000000000000000000000000000000000000
> Total Stockholder Equity
0
129,605
0
0
201,013
0
186,503
0
157,174
0
166,834
0
165,381
0
168,680
0
171,846
0
175,510
0
179,087
0
239,017
0
267,809
0
371,261
0
746,079
0
813,897
0
866,336
0
0
0
1,212,162
0
1,267,790
0
1,328,895
1,400,413
1,400,413
1,464,698
1,464,698
0
1,858,075
0
1,934,141
1,934,141
1,998,993
0
01,998,9931,934,1411,934,14101,858,07501,464,6981,464,6981,400,4131,400,4131,328,89501,267,79001,212,162000866,3360813,8970746,0790371,2610267,8090239,0170179,0870175,5100171,8460168,6800165,3810166,8340157,1740186,5030201,01300129,6050
   Common Stock
0
77,216
0
0
82,400
0
84,900
0
84,900
0
84,900
0
89,136
0
89,136
0
95,113
0
99,936
0
99,936
0
105,186
0
105,186
0
110,700
0
117,000
0
117,000
0
117,000
0
0
0
122,166
0
122,166
0
122,166
122,166
122,166
122,166
122,166
0
126,511
0
126,511
0
126,511
0
0126,5110126,5110126,5110122,166122,166122,166122,166122,1660122,1660122,166000117,0000117,0000117,0000110,7000105,1860105,186099,936099,936095,113089,136089,136084,900084,900084,900082,4000077,2160
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000-22,538000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
52,389
0
0
118,613
0
101,603
0
19,634
0
81,934
0
22,663
0
79,544
0
23,527
0
75,574
0
21,137
0
133,831
0
53,007
0
260,561
0
429,629
0
696,897
0
431,660
0
0
0
654,112
0
1,145,624
0
655,659
1,278,247
1,278,247
654,708
654,708
0
-126,511
0
-949,863
0
1,872,482
0
01,872,4820-949,8630-126,5110654,708654,7081,278,2471,278,247655,65901,145,6240654,112000431,6600696,8970429,6290260,561053,0070133,831021,137075,574023,527079,544022,663081,934019,6340101,6030118,6130052,3890



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue1,408,674
Cost of Revenue-720,934
Gross Profit687,740687,740
 
Operating Income (+$)
Gross Profit687,740
Operating Expense-512,686
Operating Income176,323175,054
 
Operating Expense (+$)
Research Development14,109
Selling General Administrative2,645
Selling And Marketing Expenses7,179
Operating Expense512,68623,933
 
Net Interest Income (+$)
Interest Income0
Interest Expense-29,227
Other Finance Cost-0
Net Interest Income-29,227
 
Pretax Income (+$)
Operating Income176,323
Net Interest Income-29,227
Other Non-Operating Income Expenses0
Income Before Tax (EBT)170,450182,196
EBIT - interestExpense = 170,450
170,450
176,512
Interest Expense29,227
Earnings Before Interest and Taxes (EBIT)199,677199,677
Earnings Before Interest and Taxes (EBITDA)263,343
 
After tax Income (+$)
Income Before Tax170,450
Tax Provision-23,165
Net Income From Continuing Ops147,285147,285
Net Income147,285
Net Income Applicable To Common Shares148,441
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,233,620
Total Other Income/Expenses Net-5,87329,227
 

Technical Analysis of Medicamen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Medicamen. The general trend of Medicamen is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Medicamen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Medicamen Biotech Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 618.85 < 687.50 < 688.97.

The bearish price targets are: 582.00 > 570.30 > 454.65.

Tweet this
Medicamen Biotech Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Medicamen Biotech Limited. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Medicamen Biotech Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Medicamen Biotech Limited. The current macd is 21.34.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Medicamen price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Medicamen. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Medicamen price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Medicamen Biotech Limited Daily Moving Average Convergence/Divergence (MACD) ChartMedicamen Biotech Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Medicamen Biotech Limited. The current adx is 19.71.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Medicamen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Medicamen Biotech Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Medicamen Biotech Limited. The current sar is 424.30.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Medicamen Biotech Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Medicamen Biotech Limited. The current rsi is 77.07. The current phase is Overbought in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Overbought in bear market: Short-term excessive buying, potential for relief decline. Consider shorting, be cautious of potential pullback. -1
  • Trending down: The RSI is trending down. -1
Medicamen Biotech Limited Daily Relative Strength Index (RSI) ChartMedicamen Biotech Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Medicamen Biotech Limited. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Medicamen price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Medicamen Biotech Limited Daily Stochastic Oscillator ChartMedicamen Biotech Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Medicamen Biotech Limited. The current cci is 345.13.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Medicamen Biotech Limited Daily Commodity Channel Index (CCI) ChartMedicamen Biotech Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Medicamen Biotech Limited. The current cmo is 68.65.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Medicamen Biotech Limited Daily Chande Momentum Oscillator (CMO) ChartMedicamen Biotech Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Medicamen Biotech Limited. The current willr is -22.04155375.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Medicamen is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Medicamen Biotech Limited Daily Williams %R ChartMedicamen Biotech Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Medicamen Biotech Limited.

Medicamen Biotech Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Medicamen Biotech Limited. The current atr is 30.89.

Medicamen Biotech Limited Daily Average True Range (ATR) ChartMedicamen Biotech Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Medicamen Biotech Limited. The current obv is 2,024,110.

Medicamen Biotech Limited Daily On-Balance Volume (OBV) ChartMedicamen Biotech Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Medicamen Biotech Limited. The current mfi is 95.90.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Medicamen Biotech Limited Daily Money Flow Index (MFI) ChartMedicamen Biotech Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Medicamen Biotech Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Medicamen Biotech Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Medicamen Biotech Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5077.068
Ma 20Greater thanMa 50442.483
Ma 50Greater thanMa 100453.277
Ma 100Greater thanMa 200508.145
OpenGreater thanClose613.900
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Medicamen with someone you think should read this too:
  • Are you bullish or bearish on Medicamen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Medicamen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Medicamen Biotech Limited

I send you an email if I find something interesting about Medicamen Biotech Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Medicamen Biotech Limited.

Receive notifications about Medicamen Biotech Limited in your mailbox!